# ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

> **NCT04429152** · PHASE3 · UNKNOWN · sponsor: **Professor Francois Venter** · enrollment: 25 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Doravirine/Lamivudine/Tenofovir

## Key facts

- **NCT ID:** NCT04429152
- **Lead sponsor:** Professor Francois Venter
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-09
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429152, "ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04429152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*